Scholar Rock Holding Co. (NASDAQ:SRRK) Receives Consensus Recommendation of "Buy" from Brokerages

Scholar Rock Holding Co. (NASDAQ:SRRK - Get Free Report) has been assigned a consensus rating of "Buy" from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $25.17.

Several equities analysts have recently weighed in on the company. Truist Financial reiterated a "buy" rating and issued a $20.00 price target on shares of Scholar Rock in a research report on Monday. Raymond James assumed coverage on Scholar Rock in a research report on Thursday. They issued a "strong-buy" rating and a $30.00 price target for the company. Piper Sandler reissued an "overweight" rating and set a $28.00 price objective on shares of Scholar Rock in a research note on Tuesday. Wedbush reissued an "outperform" rating and set a $23.00 price objective on shares of Scholar Rock in a research note on Tuesday, January 23rd. Finally, HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 19th.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK traded up $2.31 during mid-day trading on Thursday, hitting $17.76. The company had a trading volume of 1,749,788 shares, compared to its average volume of 829,393. The company has a market capitalization of $1.38 billion, a price-to-earnings ratio of -8.92 and a beta of 0.89. Scholar Rock has a 1 year low of $5.56 and a 1 year high of $21.17. The company has a current ratio of 8.80, a quick ratio of 8.80 and a debt-to-equity ratio of 0.22. The stock's 50-day moving average price is $15.55 and its 200-day moving average price is $13.32.

Insider Transactions at Scholar Rock

In other news, SVP Mo Qatanani sold 2,002 shares of the stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $15.93, for a total value of $31,891.86. Following the completion of the transaction, the senior vice president now owns 78,816 shares of the company's stock, valued at approximately $1,255,538.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Scholar Rock news, SVP Mo Qatanani sold 2,002 shares of Scholar Rock stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $15.93, for a total value of $31,891.86. Following the completion of the sale, the senior vice president now owns 78,816 shares of the company's stock, valued at approximately $1,255,538.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Edward H. Myles sold 12,459 shares of Scholar Rock stock in a transaction on Friday, December 29th. The stock was sold at an average price of $18.83, for a total value of $234,602.97. Following the completion of the sale, the chief financial officer now directly owns 168,784 shares of the company's stock, valued at approximately $3,178,202.72. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,303 shares of company stock worth $769,490. Company insiders own 26.20% of the company's stock.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Swiss National Bank increased its holdings in shares of Scholar Rock by 9.3% in the first quarter. Swiss National Bank now owns 54,000 shares of the company's stock worth $696,000 after purchasing an additional 4,600 shares during the last quarter. MetLife Investment Management LLC lifted its holdings in Scholar Rock by 54.1% during the first quarter. MetLife Investment Management LLC now owns 16,604 shares of the company's stock worth $214,000 after buying an additional 5,832 shares during the period. Rhumbline Advisers increased its position in shares of Scholar Rock by 7.0% during the first quarter. Rhumbline Advisers now owns 29,405 shares of the company's stock worth $379,000 after purchasing an additional 1,918 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Scholar Rock by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 178,984 shares of the company's stock worth $2,307,000 after purchasing an additional 34,416 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Scholar Rock by 2.7% during the first quarter. Vanguard Group Inc. now owns 1,490,795 shares of the company's stock worth $19,217,000 after purchasing an additional 38,917 shares in the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.